SCHEMBL12411159

SCHEMBL12411159

CNc1cc(C)nc(NC(C)C)n1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NOS3 P29474 1/20 0.48
▸ NOS2 P35228 1/20 0.48
▸ LMNA P02545 2/20 0.44
▸ CYP1A2 P05177 1/20 0.44
▸ CYP2C19 P33261 1/20 0.44
▸ NPSR1 Q6W5P4 1/20 0.44
▸ ALDH1A1 P00352 4/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.43
▸ ALOX15 P16050 1/20 0.41
▸ GAA P10253 3/20 0.41
▸ TDP1 Q9NUW8 1/20 0.41
▸ EHMT2 Q96KQ7 2/20 0.40
▸ EHMT1 Q9H9B1 2/20 0.40
▸ MAPK1 P28482 2/20 0.39
▸ NUDT1 P36639 1/20 0.38
▸ KCNH3 Q9ULD8 3/20 0.38
▸ KMT2A Q03164 2/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ OGG1 O15527 1/20 0.38
▸ TRPM8 Q7Z2W7 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16608839 0.88 LMNA (0.46) LMNACYP1A2CYP2C19NPSR1ALDH1A1
SCHEMBL12411171 0.88 GAA (0.46) NOS3NOS2LMNACYP1A2CYP2C19
SCHEMBL12410776 0.83 LMNA (0.52) LMNACYP1A2CYP2C19NPSR1ALDH1A1
SCHEMBL12499637 0.81 NOS3 (0.58) NOS3NOS2LMNACYP2C19NPSR1
SCHEMBL19709381 0.80 NOS3 (0.41) NOS3NOS2ALDH1A1L3MBTL1ALOX15
SCHEMBL12411179 0.78 L3MBTL1 (0.52) LMNACYP1A2CYP2C19NPSR1L3MBTL1
SCHEMBL12411153 0.76 TAAR1 (0.54) LMNACYP1A2CYP2C19NPSR1ALDH1A1
SCHEMBL12410906 0.74 GAA (0.52) LMNACYP1A2CYP2C19NPSR1ALDH1A1
SCHEMBL12411157 0.74 HRH4 (0.51) NOS3NOS2LMNACYP1A2CYP2C19
SCHEMBL12411156 0.74 LMNA (0.49) LMNACYP1A2CYP2C19NPSR1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023064586-A1 NOVEL MODULATORS OF EHMT1 AND EHMT2 AND THERAPEUTIC USE THEREOF TANGO THERAPEUTICS, INC. (US) 2023-04-20 — — WO disclosed
US-20130289013-A1 IMIDAZO[1,2-a]PYRIDINE COMPOUNDS SUNOVION PHARMACEUTICALS INC. 2013-10-31 — — US disclosed
US-20110166146-A1 IMIDAZO[1,2-a]PYRIDINE COMPOUNDS SUNOVION PHARMACEUTICALS INC. (US) 2011-07-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110166146-A1 IMIDAZO[1,2-a]PYRIDINE COMPOUNDS PAICS, ITPA, DPYD NOS3 3545/4885NOS2 3122/4885LMNA 2528/4885
US-20130289013-A1 IMIDAZO[1,2-a]PYRIDINE COMPOUNDS PAICS, ITPA, DPYD NOS3 3545/4885NOS2 3122/4885LMNA 2528/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback